entertainment -WSS

entertainment

author：explore 2025-09-29 01:06:24 - browse：53355

Adam's take main illustration — Molly Ferguson/STAT

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study.

A looming test for neoantigen cancer vaccines

Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that is resistant to immunotherapies like PD-1/PD-L1 inhibitors.

The Gritstone vaccine is designed to train a patient’s own T cells to recognize and kill cancer cells by targeting mutated cancer proteins, called neoantigens, that are unique to a patient’s own tumor. It’s a relatively new approach for cancer vaccines — made possible by powerful and relatively inexpensive genomic sequencing of tumors – that is intended to overcome all the previous failures in the field. Gritstone’s effort is also similar to one being used by Moderna and Merck that has reported encouraging results in melanoma — and is now being investigated in a Phase 3 study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

entertainment

leisure time

WSS

FDA clears AI tool for detecting skin cancer

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Sana to lay off nearly a third of staff, de

Biotech venture capitalists face new demands from investors

Medicare Advantage today, explained in one chart

A virus, fished out of a lake, may have saved a man’s life

entertainment

entertainment

A looming test for neoantigen cancer vaccines

explore

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Merck, J&J, and long Covid

Sports medicine is finally prioritizing gender equality

Histogen: Failed biotech offers rare public look inside

Medical records are filled with copy

FDA authorizes Novavax’s updated Covid

George Santos makes 1st court appearance after pleading not guilty to 13 counts

When women are denied an abortion, their children fare worse than peers

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biotech venture capitalists face new demands from investors

leisure time

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Histogen: Failed biotech offers rare public look inside

Sana to lay off nearly a third of staff, de

FDA rejects Alnylam's heart disease treatment over insufficient data

AI generated plenty of interest at JPM but not a lot of trust

eGenesis tests gene

entertainment

leisure time

focus

explore